Clinical Trials · NCT07277439
Phase II Trial of Neoadjuvant Thymalfasin, PD-1 Inhibitor, and Chemoradiotherapy for cStage III GEJ Adenocarcinoma
- Phase
- Phase 2
- Recruitment status
- Recruiting
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Enrollment
- 48
- Start date
- Dec 2025
- Locations
- 1 site, China
- Primary endpoint
- Complete pathological response (pCR) rate